Abstract
Antipsychotic medications are the cornerstone of schizophrenia treatment but non-adherence is a challenge in the management of the disease, 1 with estimates of non-adherence as high as 50%. 2, 3 Poor adherence is associated with worse prognosis as well as greater risks of psychiatric hospitalizations, emergency psychiatric services use, relapse, and suicide attempts. [4] [5] [6] Implementing strategies targeting modifiable factors influencing adherence to antipsychotic medication is key to avoiding adverse consequences of non-adherence. The introduction of second generation long-acting injectable (LAI) antipsychotics in the mid-2000s increased the possibility of adherence by combining a more favourable neurologic safety profile than first generation LAIs with the persistence of first generation LAIs. LAIs are associated with greater adherence and persistence than oral antipsychotics but, unlike oral antipsychotics, LAIs are administered less frequently (i.e., bi-weekly or monthly versus daily) and are not self-administered, which may also impact adherence. [7] [8] [9] [10] Interventions incorporating reminders, cues, or reinforcements to take or refill medications are effective in enhancing adherence to oral antipsychotic medication [11] [12] [13] and phone appointment reminders may reduce non-attendance in psychiatric outpatient departments. [14] [15] [16] The objective of this study was to evaluate the effectiveness of an institutional medication adherence program (IMAP), consisting of phone calls to remind patients of upcoming and of missed appointments, on adherence and psychiatric hospitalization rates among schizophrenia patients taking the LAI antipsychotic treatment, risperidone (RLAI).
METHODS

Design and Study Population
We randomly contacted by mail and then by phone, psychiatric centres or hospitals with a psychiatric ward across 17 French regions. In total, 104 physicians from 88 different centres were contacted, 71 physicians from 52 centres agreed to participate, and 44 physicians from 36 centres enrolled at least one patient in the study. Patient recruitment began in June 2009 and ended in May 2010, after 514 patients were recruited.
Eligible patients were those with a DSM-IV diagnosis of schizophrenia, aged 18 to 65 years, treated with RLAI, hospitalized for ≤3 months at enrolment, and receiving outpatient treatment from a participating psychiatric centre. Patients with limited life expectancy, enrolled in a clinical trial, not enrolled in the national health care system, or who did not understand French were not eligible.
Institutional Medication Adherence Program
The IMAP design was based on the hypothesis that more frequent interactions between schizophrenia patients and their health care providers could result in increased adherence and better outcomes. The IMAP consisted of having the primary provider call the patient within 48 hours of their scheduled RLAI injection. If the patient missed their appointment, the provider would call the patient within 3 days to remind them of their scheduled injection or, if the patient could not be reached, the patient's contact person. The IMAP was applied at the discretion of the centres.
Centres were categorized as IMAP-compliant if they applied the program, over the one year study period, to ≥50% of their patients' scheduled RLAI injections, provided that information regarding IMAP application was available for ≥80% of the scheduled RLAI injections for that centre. Centres not meeting these criteria were categorized as being not IMAP compliant.
Outcomes
Psychiatric hospitalization, a proxy for relapse, was defined as a hospitalization ≥24 hours in a psychiatric ward or for psychiatric reasons. Hospitalizations separated by less than seven days were considered to be related to the first hospitalization and counted once.
Patients were categorized as being adherent to RLAI if they had received ≥80% of their scheduled injections within 5 days of the scheduled date over the one year study period. A cutoff of 80% was used to categorize patients as adherent to be consistent with the majority of studies on medication adherence 17 and because it was endorsed by an expert consensus panel as an appropriate cutoff in schizophrenia. 1 If either the scheduled injection date or date of injection were missing, adherence to that RLAI injection could not be determined. Non-adherent patients were those for whom adherence could not be determined for ≥20% of their scheduled injections or who showed up within 5 days of their scheduled injection date for ,80% of their RLAI injections.
Data Collection and Data Elements
At In addition to the elements mentioned above, data on mortality (date and cause) and psychiatric hospitalizations (number and duration) were collected at 3, 6, 9, and 12 months from the patient's medical record.
Follow-Up
Patients were followed from cohort entry to 12 months, death, or loss to follow-up. In accordance with a previously described methodology, 18 follow-up during any given trimester (i.e., 3 months) was categorized as indefinite if data on hospitalizations and antipsychotic use was missing. Trimesters categorized as indefinite were not included in the follow-up but patients could re-enter the cohort during subsequent trimesters.
Statistical Analysis
Patient characteristics are reported for the cohort as well as by IMAP compliance and patient adherence using percentages for categorical variables and means and standard deviations and/or medians and 25% and 75% percentiles for continuous variables. Characteristics of centres participating in the study are also reported.
We calculated psychiatric hospitalization rates per 100 person-years as the number of psychiatric hospitalizations divided by the number of person-years at risk of hospitalization multiplied by 100, with 4 trimesters roughly equivalent to one person-year. We estimated hospitalization rates and calculated 95% confidence intervals (CI) overall and by IMAP compliance and patient adherence. Using Poisson regression, we report unadjusted relative rates (RR) and 95% CIs comparing patients treated in IMAP-compliant versus noncompliant centres and adherent versus non-adherent patients. To derive adjusted estimates, we built separate propensity scores for IMAP-compliance (patients treated at IMAP compliant vs. non-compliant centres) and adherence (yes vs. no), including sociodemographics, schizophrenia severity, psychiatric comorbidities, suicidality, somatic comorbidities, antipsychotic use, and centre-level variables. Propensity scores were categorized into quintiles and included directly in the Poisson regression model. We assessed the possibility of an interaction between IMAP compliance and patient adherence by deriving stratified estimates and by including an interaction term in the model. When missing data was ,10%, we imputed the mean for continuous variables and the mode for categorical variables and when ≥10% of data were missing for a given variable, we included a level representing the missingness in the outcome model. All analyses were conducted using SAS ® 9.3 (SAS Institute, Cary, NC).
Ethics
The study was conducted in accordance with ethical principles stated in the Declaration of Helsinki and was approved by the French privacy and data protection authority and the French national board of physicians. Informed consent was obtained from patients or from the patient's guardian.
RESULTS
Of the 84 centres that were contacted, 52 (61.9%) accepted to participate in the study and 36 (69.2%) followed up at least one patient. Participating centres were predominantly general (vs. psychiatric) centres (68.6%), treating a mean of 250.1 (Standard Deviation [SD]:195.1) schizophrenia patients, had a mean of 25.4 (SD: 13) beds, and .80% were located outside the Paris region. The mean number of patients recruited per centre was 14.5 (SD: 12.1; range: 1-49).
In total, 514 patients were enrolled, 506 (98.4%) were followed-up and 492 (95.7%) followed up to 12 months. Patients had a mean age of 38.7 years (SD: 11.0), 64.6% were male, 72.1% had less than a high school education, 21.1% were working, 61.7% were living independently, ( Table 1 ). The predominant form of schizophrenia was paranoid (62.3%) and 60.4% had a past-year psychiatric hospitalization. There were 163 hospitalizations over 502 patient-years of follow-up. The rate of psychiatric hospitalizations per 100 person-years was 32.5 (95% [CI]: 27.7 to 37.9).
Of the 36 centres, 15 (41.7%) centres treating 243 (48.0%) patients were categorized as IMAP-compliant and 21 (58.3%) centres treating 263 (52.0%) patients were categorized as being IMAP non-compliant. Of the non-compliant centres, 5 centres treating 31 patients did not provide sufficient data to categorize their compliance, including 2 centres which provided no data. Compared to compliant centres, non-compliant centres were less likely to be specialized in psychiatry (45.5% vs. 54.5%) and had a smaller mean number of psychiatric hospital beds (23.8 vs. 28.6).
Patients treated by IMAP-compliant compared to non-compliant centres were less likely to be living independently (56.4% vs. 66.5%) and currently working (18.5% vs. 23.6%) but were more likely to be on antipsychotic monotherapy (60.5% vs. 54.0%) ( Table 1) . Patients treated by IMAP-compliant centres also had lower proportions of patients using all antipsychotic classes, and maximum lifetime CGI-S, BPRS, and GAF scores indicative of slightly lower schizophrenia severity.
Overall, 368 (72.3%) patients were categorized as adherent to their RLAI regimen. Of the 138 patients categorized as non-adherent, adherence could not be determined for more than 20% of reported scheduled RLAI injections for 62 patients (44.9%). Non-adherent patients appeared to be slightly healthier than adherent patients as they were more likely to be working (24.6% vs. 19.8%) and less likely to have been hospitalized in the past-year (53.2% vs. 63.3%) ( Table 1) . Mean scores on the maximum lifetime CGI-S, BPRS, and GAF were comparable across adherence as was antipsychotic use.
Patients treated in IMAP-compliant centres had lower psychiatric hospitalization rates per 100 person-years (25.3; 95% CI: 19.3-32.4) than patients treated by centres who were not compliant (39.2; 95% CI: 32.0-47.6) ( Table 2 ). The effect of IMAP compliance on reducing hospitalization rates persisted after adjusting for patient-and provider-level variables (RR50.78; 95% CI: 0.47-1.27). Unadjusted psychiatric hospitalizations rates per 100 person-years were 32.8 (95% CI: 27.2-39.2) and 31.7 (95% CI: 23.0-42.7) among adherent and non-adherent patients, respectively ( Table 2 ). The RR of psychiatric hospitalizations after adjustment for patient-and provider-level factors was 0.92 (95% CI: 0.59-1.44).
The effect of IMAP-compliance differed by adherence. Among adherent patients (N5368), patients treated in IMAP-compliant centres had lower hospitalization 
Sensitivity Analysis
When the analysis was restricted to centres whose IMAP compliance was known and to patients whose adherence was known, power was reduced but results were generally robust (Supplemental Table 1 ). When the criteria to categorize centres as IMAP compliant was raised from applying the intervention to 50% or more of their patients' scheduled RLAI injections to 80%, the effect of the IMAP increased only slightly (Supplemental Table 2 ).
DISCUSSION
In this prospective cohort study, we found that a telephone call reminding patients of an upcoming appointment for their antipsychotic injection and a follow-up call in case of a missed appointment resulted in high level of adherence (almost 75% over 1 year) among schizophrenia patients taking RLAI, treated in the outpatient setting. This intervention was also associated with a reduction in the rate of psychiatric hospitalizations. The intervention may have been more effective at reducing psychiatric hospitalizations among patients who were non-adherent to their LAI regimen.
The proportion of patients who were categorized as adherent was high: nearly 75% over one year of follow-up. The true level of adherence in our study is likely higher as almost half (44.9%) of patients whose adherence could be determined were classified as non-adherent. The level of adherence observed in our study is much higher than the level of LAI adherence reported in a recent study. Among Medicaid schizophrenia patients, adherence (measured as proportion of days covered as ≥0.80) in the 6-month period following a schizophrenia-related hospitalization was 42.8% for any LAI (N5340) and, slightly higher, 52.5% (N5183) for second generation LAIs. 19 The proportion of Medicaid patients who continue to be adherent to their LAI regimen at 12 months is likely to be lower. While we cannot confirm that the high level of adherence in our study is due to the IMAP, our findings suggest that the intervention likely had a positive effect on patient adherence. LAIs have been shown to decrease rates of relapse/psychiatric hospitalizations compared to oral antipsychotics in randomized controlled trials (RCTs), 20 meta-analyses of RCTs, 21 and observational studies of schizophrenia outpatients. 7, 18, 22, 23 Some studies, however, have failed to demonstrate advantages of LAIs versus oral antipsychotics on relapse/hospitalization rates, 24 including RCTs. 25, 26 This discrepancy may be attributable to attenuating differences in adherence between LAI and oral antipsychotic users; in RCTs, non-adherent patients may be underrepresented, 27 in inpatient settings adherence will be more closely controlled than in outpatient settings, and, in outpatient settings, changes from daily to bi-monthly or monthly administrations may negatively influence adherence for patients who have difficulties remembering appointments and managing their time. Reminder-based interventions can address the latter source of non-adherence, which may be due to symptoms of schizophrenia such as disorganization, lack of insight, or cognitive dysfunction rather than a lack of willingness to take medications. Indeed, in this study, patient support in the form of well-timed, direct phone calls was associated with a reduction in psychiatric hospitalization rates. In addition, the effect of the IMAP appeared to be greater among non-adherent patients, who also tended to have a higher prevalence of disorganized schizophrenia and greater symptom severity. A complementary strategy to improve adherence and, concomitantly, outcomes in schizophrenia outpatients treated with LAIs may therefore consist of reminder phone calls for appointments and follow-up phone calls for no-shows.
The results of this study must be interpreted in the context of certain limitations. Firstly, IMAP compliance and patient adherence data was not always complete; IMAP compliance could not be determined for centres treating approximately 6% of patients and adherence could not be determined for 12% of patients. The results of our sensitivity analyses, however, suggest that centres not collecting information on their application of MAP were unlikely to be compliant since removing patients whose adherence was unknown did not have a substantial impact on the estimates. Another limitation of this study was the lack of power; likely due to the success of the intervention, there were few patients who were non-adherent (,150 patients), which limited the ability to detect a significant interaction between IMAP compliance and patient adherence. The effectiveness of the intervention was evaluated over a one-year period and it is unclear whether "reminder fatigue" would attenuate the effectiveness of the IMAP over longer periods, such as 2, 5, or 10 years. Lastly, the IMAP does not address non-adherence stemming from reasons other than lack of illness insight or forgetfulness (e.g., side effects, drug resistance, centre experience with LAI administration) and residual confounding cannot be ruled out. Ours is one of only a handful of studies evaluating interventions to improve adherence to LAIs 28,29 and the first to assess the effectiveness of a reminder-based intervention. We evaluated the effect of an intervention on over 500 patients, which were followed for one year with very little attrition. We collected data such that we could evaluate and control for factors known to affect adherence, such as sociodemographics, disease severity, social support, and alcohol/substance abuse. 2 Lastly, we applied broad inclusion and few exclusion criteria in order to ensure that the results of this study would be generalizeable to the French outpatient schizophrenia population treated with LAIs.
Adherence may be modifiable risk factor for relapse but it often goes undetected. While adherence to LAIs may be higher than with oral antipsychotics, we demonstrated that outcomes among schizophrenia outpatients taking LAIs can be further improved by implementing an IMAP consisting of a telephone-based intervention, particularly among patients with difficulties adhering to their treatment regimen. One of the main advantages of LAIs is that non-adherence is immediately noticeable through direct refusal or missed appointments but it does not address nonadherence stemming from deficiencies in attention and memory. Calling patients to remind them of an upcoming appointment or following up with them via phone in case of a missed appointment serves as both a reminder and as reinforcement to adhere to LAI therapy. Outpatient care for schizophrenia could be improved by implementing a telephone-based IMAP for patients taking LAIs, as a relatively low cost, low burden strategy to improve adherence and avoid costly hospitalizations due to relapse. Future studies should evaluate the cost-effectiveness of the program, assess effectiveness of reminders using text messaging, and explore barriers to program implementation at centres.
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